Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
1 clinical trials · Condition
◉ Watch Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
| Record | Firm | Date |
|---|---|---|
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (NCT01844765) | Novartis Pharmaceuticals | 2013-08-20 |
Track Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.